Lp(a) Testing in Primary Prevention: Cost-Effective Strategy to Reduce Cardiovascular Risk
Atherosclerosis has shared a post on LinkedIn:
“Lp(a) Testing: A Cost-Saving Tool for Cardiovascular Prevention
High Lp(a) levels are a known cardiovascular risk factor, but is testing for Lp(a) worth it from a healthcare perspective?
A recent microsimulation study modeled 10,000 adults aged 40–69 without prior CVD from the UK Biobank. The study evaluated Lp(a) testing in individuals not initially high-risk. Those with Lp(a) ≥105 nmol/L were reclassified as high-risk and received statins and blood pressure–lowering therapy.
Key findings:
- Out of 10,000 individuals, 1,807 had their treatment modified based on Lp(a).
- 217–255 quality-adjusted life years gained in Australia and the UK.
- Cost-effectiveness ratios: $12,134 AUD (cost-effective) and −£3,491 GBP (cost-saving).
- From a societal perspective, testing saved $85 AUD and £263 GBP per person.
- Modeling across multiple countries showed Lp(a) testing to be cost-saving everywhere.
Takeaway: Lp(a) testing in primary prevention reclassifies risk, guides therapy, and saves costs—supporting its adoption as a preventive strategy against CVD.
This study makes a compelling case for integrating Lp(a) measurement into routine cardiovascular risk assessment.”
Title: Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis
Author: Jedidiah I. Morton, Florian Kronenberg, Magdalena Daccord, Nicola Bedlington, Marius Geant, Tobias Silberzahn, Zhenyue Chen, Jean-Luc Eisele, Bogi Eliasen, Mariko Harada-Shiba, Marc Rijken, Albert Wiegman, George Thanassoulis, Pia R. Kamstrup, Iñaki Gutierrez-Ibarluzea, Pablo Coral, Raul D. Santos, Erik Stroes, Michal Vrablik, Gerald F. Watts, Christie M. Ballantyne, Samia Mor, Børge G. Nordestgaard, Kausik K. Ray, Stephen J. Nicholls, Zanfina Ademi
Read the full article here.
Stay updated with Hemostasis Today.
-
Nov 1, 2025, 18:00Kathleen Freson to Speak at the EHA SWG Scientific Meeting
-
Nov 1, 2025, 17:38Joshua Muia on Genetic Alterations Affecting ADAMTS13 Maturation at IPS 2025
-
Nov 1, 2025, 17:19Michael Makris Shares 2024 Annual Global Survey from the WFH
-
Nov 1, 2025, 16:45Erin VanDyke: This Month Was Full of Meaningful VTE Moments
-
Nov 1, 2025, 14:14Congratulations to South Africa’s first WSO Certified Essential Stroke Centers!
-
Oct 31, 2025, 13:47Bethany Brown and Colleagues Present Recommendations on DEHP Alternatives
-
Oct 30, 2025, 07:52Haemophilia B - An illustrative review of current challenges and opportunities
-
Oct 30, 2025, 05:14Umberto Pensato on Reperfusion Outcomes in Stroke
-
Oct 29, 2025, 07:39Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
-
Oct 29, 2025, 07:38Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 1, 2025, 17:04Ozlem Fidanci: Recognizing The Signs of a Stroke Can Save Someone You Love
-
Nov 1, 2025, 15:51Gülşah Türkoğlu: On World Stroke Day, We Came Together to Commemorate This Important Global Health Occasion
-
Nov 1, 2025, 15:05Nusaiba Masnurah Delivered A Speech on Surviving Thrombotic Events Werfen’s EEMEA Seminars
-
Nov 1, 2025, 14:47Rob Verhaeren at WSC 2025: Discover How Philips Technology Helps Accelerate Stroke Response
-
Nov 1, 2025, 13:58Rena Hirani Awarded the Inaugural James Isbister Prize at the Blood ISBT 2025